0001209191-20-062613.txt : 20201209 0001209191-20-062613.hdr.sgml : 20201209 20201209190508 ACCESSION NUMBER: 0001209191-20-062613 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201207 FILED AS OF DATE: 20201209 DATE AS OF CHANGE: 20201209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BALDO LANCE CENTRAL INDEX KEY: 0001780773 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 201379012 MAIL ADDRESS: STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION STREET 2: 1551 EASTLAKE AVE E STE 200 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-07 0 0001478320 Adaptive Biotechnologies Corp ADPT 0001780773 BALDO LANCE C/O ADAPTIVE BIOTECHNOLOGIES CORP. SUITE 200 SEATTLE WA 98102 0 1 0 0 Chief Medical Officer Common Stock 2020-12-07 4 M 0 6250 7.80 A 6250 D Common Stock 2020-12-07 4 S 0 780 48.79 D 5470 D Common Stock 2020-12-07 4 S 0 3000 50.14 D 2470 D Common Stock 2020-12-07 4 S 0 2470 51.26 D 0 D Stock Option (Right to Buy) 7.80 2020-12-07 4 M 0 6250 0.00 D 2029-05-06 Common Stock 6250 381250 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $48.05 to 48.99, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $49.63 to 50.56, inclusive. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $50.63 to 51.50, inclusive. The options vested with respect to 1/4 of the shares on May 6, 2020, with 1/48 of the shares vesting thereafter at the end of each full month of continuous service until fully vested. /s/ Lance Baldo by Eric L. Billings, attorney-in-fact 2020-12-09